ST. LOUIS, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the launch of its Niobe® remote magnetic navigation system at Kakogawa Central City Hospital, which becomes the second of four systems shipped to Japan to have been installed. Opened July 1, Kakogawa Central City Hospital combines the former Kakogawa East City Hospital and Kakogawa West City Hospital into one 600-bed, state-of-the-art facility located approximately 280 miles southwest of Tokyo. On June 11 and 12, the hospital highlighted its new Niobe system and offered tours of the electrophysiology (EP) lab as part of an opening ceremony for the local healthcare community, media and residents.
“The introduction of the Stereotaxis magnetic navigation platform has brought great excitement to interventional medicine in Japan, and we are very pleased to be the first in the prefecture to offer this highly advanced treatment for cardiac arrhythmias,” said Yoshio Onishi, Chief Executive Officer of Kakogawa Central City Hospital. “Our new building and cutting-edge therapies are part of our commitment to supporting the health and wellness of our citizens throughout their lifetime.”
Katsunori Okajima, M.D., Department Manager, Cardiovascular Internal Medicine, said, “I am eager to employ the Niobe system with my complex EP cases, having observed first-hand its ease of use, exceptional mapping and ablation capabilities in all areas of the heart, and significantly reduced complication risk, all benefits supported by an overwhelming number of clinical studies from around the world.”
Okajima recently visited the U.S. to observe several procedures with the Niobe system and received comprehensive training on the system at Kakogawa prior to the July 20 clinical launch.
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect™ catheter advancement system is available for use in the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.